DAFTAR PUSTAKA

[1] P. K. Indonesia, *Profil kesehatan indonesia 2022*. 2022.

[2] D. Yuliana, U. M. Indonesia, S. Selatan, U. M. Indonesia, and S. Selatan, "Literatur Review: Perkembangan Pengobatan Kemoterapi Kankrer Payudara," vol. 2, no. 1, pp. 32–40, 2024.

[3] A. Statements, "Breast Cancer , Version 5 . 2025 Featured Updates to the NCCN Guidelines," vol. 23, no. 11, pp. 426–436, 2026, doi: 10.6004/jnccn.2025.0053.

[4] Y. Yan and J. Zhang, "Mechanisms of tamoxifen resistance : insight from long non-coding RNAs," no. October, pp. 1–9, 2024, doi: 10.3389/fonc.2024.1458588.

[5] K. J. Jerzak *et al.*, "HR + / HER2 – Advanced Breast Cancer Treatment in the First-Line Setting : Expert Review," pp. 5425–5447, 2023.

[6] M. Rizki *et al.*, "Boesenbergia Pandurata as an Anti-Breast Cancer Agent : Molecular Dock- ing and ADMET Study," pp. 606–626, 2022, doi: 10.2174/1570180819666211220111245.

[7] B. Na, D. L. Aulifa, A. Aly, and A. Shofwan, "Kalkon dan Potensinya sebagai Antikanker : Literatur Review Chalcone and its Potential as Anticancer : Literature Review," vol. 11, no. 4, 2024, doi: 10.15416/ijcp.2022.11.4.360.

[8] M. Claudya, D. Kesuma, A. Kirtishanti, I. G. A. Sumartha, and M. A. Amelia, "Activities of Chalcone Derivatives from Boesenbergia rotunda Against Human Estrogen Receptor Alpha of Breast Cancer by In Silico," vol. 10, no. 10, pp. 8117–8126, 2024, doi: 10.29303/jppipa.v10i10.8865.

[9] C. Sulaiman, B. P. George, I. Balachandran, and H. Abrahamse, "Cancer and Traditional Medicine : An Integrative Approach," pp. 1–16, 2025.

[10] I. D. Sipayung, S. Lumbanraja, and A. Fitria, "Analisa Faktor-Faktor yang Berhubungan dengan Kanker Payudara (Ca Mammae) di RSUD dr Pirngadi Medan Tahun 2020 Analysis of Associated with Breast Cancer (Ca Mammae) at dr Pirngadi Hospital Medan in 2020," vol. 8, no. 1, pp. 468–476, 2022.

[11] N. Padauleng, M. K. Prof.Dr.apt.Mustofa, and P. D. Dra. Dewajani Purnomosari, M.Si., "Potensi senyawa kalkon-3 sebagai antikanker payudara: Kajian aktivitas molekuler invitro pada galur sel T-47D, MCF-7, MDA-MB-231, dan invivo pada tikus yang diinduksi DMBA," 2023.

[12] N. M. Isa *et al.*, "boesenbergin A , a chalcone isolated from Boesenbergia rotunda (L .) (fingerroot) In vitro anti-inflammatory , cytotoxic and antioxidant activities of boesenbergin A , a chalcone isolated from Boesenbergia rotunda (L .) (fingerroot)," vol. 45, no. June, 2023, doi: 10.1590/S0100-879X2012007500022.

[13] M. Jannah, "Analisis Aktivitas Anti Kanker Senyawa Tumbuhan Maja (Aegle Marmelos) Terhadap Penyakit Kanker Payudara Dengan Metode Penambatan Molekuler (Molecular Docking)," Universitas Islam Negeri

Alauddin Makassar, 2021.
[14] N. S. Wagle *et al.*, “Cancer treatment and survivorship statistics, 2025.,” *CA. Cancer J. Clin.*, vol. 75, no. 4, pp. 308–340, 2025, doi: 10.3322/caac.70011.
[15] Z. Long, Y. Qiu, Z. Long, and Z. Jin, “Epidemiology of breast cancer in Chinese women from 1990 to 2021 : a systematic analysis and comparison with the global burden,” *BMC Cancer*, 2025, doi: 10.1186/s12885-024-13336-w.
[16] Hao Gu *et al.*, “Global burden and trends of breast cancer: GLOBOCAN 2022 estimates of incidence and mortality in 185 countries.,” *Chin. Med. J. (Engl).*, 2025.
[17] F. Syamsuddin, H. Damansyah, Harismayanti, S. N. Ahmad, S. Nurhaliza, and Bella Aprilia R. Taha, “Faktor Faktor Yang Berhubungan Dengan Kejadia Ca Mamae di RSUD Provinsi Gorontalo,” vol. 10, no. 1, 2025.
[18] J. Biostatistik, I. Kesehatan, A. Triana, I. Aulia, and Y. Handayani, “Determinan Perilaku Pemeriksaan Payudara Sendiri (SADARI) Pada Mahasiswi Fakultas Kesehatan Masyarakat Universitas Indonesia Tahun 2022 Determinan Perilaku Pemeriksaan Payudara Sendiri (SADARI) Pada Mahasiswi Fakultas Kesehatan Masyarakat Universitas Indonesia Tahun 2022 Determinants of Breast Self-Examination Behavior Among Female Students in Faculty of Public Health Universitas Indonesia,” vol. 3, no. 1, 2023, doi: 10.7454/bikfokes.v3i1.1034.
[19] A. Osborne, Q. Estiningtyas, S. Adnani, and B. O. Ahinkorah, “Breast cancer incidence in Indonesia : a sex- disaggregated analysis using WHO health equity assessment toolkit data,” 2025.
[20] S. R. Alimun, Ks. Rijal, I. M. Musa, R. Purnamasari, and F. Irsandy, “Analisis Faktor Risiko Kanker Payudara Sity,” *J. Mhs. Kedokt.*, vol. 04, no. 06, pp. 473–484, 2024.
[21] N. M. Atallah, C. Quinn, and E. Rakha, “HER2 expression in breast cancer : evidence gaps and challenges Check for updates,” 2026.
[22] J. Li *et al.*, “Recent Research Advances in HER2-Positive Breast Cancer Concerning Targeted Therapy Drugs.,” *Molecules*, vol. 30, no. 14, Jul. 2025, doi: 10.3390/molecules30143026.
[23] M. F. Adidaifa, “Jurnal Biologi Tropis HER2-Positive Breast Cancer : A Literature Review,” 2025.
[24] B. Wu *et al.*, “Targeting estrogen receptor alpha in breast cancer for novel therapies resistance mechanisms and future directions,” 2026.
[25] M. Palaniappan, “Current Therapeutic Opportunities for Estrogen Receptor Mutant Breast Cancer,” 2024.
[26] A. N. G. Msph *et al.*, “Breast cancer statistics 2024,” no. August, pp. 477–495, 2024, doi: 10.3322/caac.21863.
[27] A. Sivasailam *et al.*, “Estrogen receptor alpha dynamics and plasticity during endocrine resistance,” *Biol. Direct*, 2025, doi: 10.1186/s13062-025-00653-8.
[28] R. Pereira, M. P. Coelho, and M. M. Gaspar, “Targeting Triple-Negative Breast Cancer : A Special Focus on Phototherapy and Nanomaterials,” vol. 2, pp. 1–26, 2026.

[29] H. Yang *et al.*, "Triple-Negative Breast Cancer Brain Metastasis : A Comprehensive Review of Epidemiology , Molecular Pathobiology , and Therapeutic Frontiers," pp. 1–16, 2026.
[30] V. Lebedeva, M. Ebbinghaus, J. V. Hidalgo, and O. Hardt, "Triple-Negative Breast Cancer Unveiled : Bridging Science , Treatment Strategy , and Economic Aspects," vol. 2, pp. 1–27, 2025.
[31] A. Hassan and C. Aubel, "The PI3K / Akt / mTOR Signaling Pathway in Triple-Negative Breast Cancer : A Resistance Pathway and a Prime Target for Targeted Therapies," pp. 1–18, 2025.
[32] S. Alharbi, F. F. Qasem, M. T. Talebi, N. E. Omran, R. Hamoudi, and R. Harati, "Immunotherapy Approaches for the Treatment of Triple-Negative Breast Cancer," pp. 1–38, 2026.
[33] A. J. Onyewuchi *et al.*, "Triple Negative Breast Cancer: A Comprehensive Review of Epidemiology, Biology, and Management," *J. Am. Med. Sci. Res.*, vol. 4, pp. 88–99, Oct. 2025, doi: 10.51470/AMSR.2025.04.02.88.
[34] P. Ca, M. Di, R. Sakit, and M. Tangerang, "Hubungan Kepatuhan Menjalani Kemoterapi dengan Kualitas Hidup Pasien Ca Mamae di RUmah Sakit Mayapada Tanggerang tahun 2025," *Glob. Res. Innov. J.*, vol. 1, pp. 2206–2216, 2025.
[35] K. P. Trayes and T. Jefferson, "Breast Cancer Treatment," pp. 171–178, 2021.
[36] C. E. Puspitasari, B. Hawarikatun, J. Annisa, and M. M. Yasykurah, "Perkembangan targeted therapy pada kanker payudara dengan pertimbangan luaran biaya dan kualitas hidup : narrative review," vol. 5, no. 2, 2024.
[37] D. Mar, F. Yuliastuti, D. Farmasi, F. I. Kesehatan, and U. M. Magelang, "Pola Pengobatan Kanker Payudara dengan Kemoterapi dan Pre Kemoterapi Pada Pasien Peserta JKN Kanker Payudara Di RSUD Kota Yogyakarta," vol. 9, no. 2, pp. 574–584, 2023.
[38] P. Kanker, P. Di, and R. Fatmawati, "Efektivitas Penggunaan Obat KEmoterapi Neoadjuvant Pada Pasien Kanker Payudara di RSUP Fatmawati Jakarta," *J. pharma santika*, vol. 9, no. 1, pp. 93–106, 2025.
[39] K. Payudara and S. Tinjauan, "Intervensi Nonfarmakologis Sebagai Solusi Kelelahan pada Pasien Kanker Payudara : Sebuah TInjauan Sistematik," *Melahayati Nurs. J.*, vol. 7, no. 10, pp. 4219–4236, 2025.
[40] A. Clemmons, A. Gandhi, A. Clarke, S. Jimenez, T. Le, and E. Healthcare, "Premedications for Cancer Hematology / Oncology Provider," pp. 810–832, 2021.
[41] W. Rajabto, B. Brahma, R. I. Putri, and H. Indrawati, "Dual Anti-HER2 Combination with Chemotherapy as First- line Treatment for HER2-positive Metastatic Breast Cancer," vol. 57, no. 4, pp. 538–540, 2025.
[42] H. Lawrenti, "Terapi Kanker Payudara Stadium Lanjut HER2 (+)," vol. 50, no. 2, pp. 565–569, 2023.
[43] M. Lema *et al.*, "Evidence-Based Consensus on the Diagnosis and Treatment of Advanced HER2-Positive and HER2-Low Breast Cancer in Colombia," pp. 1–22, 2026.

[44] X. Li and T. Huang, “Advances in the intrinsic signaling pathway interactions and clinical translation of HR + / HER2 + breast cancer,” *Breast Cancer*, vol. 32, no. 6, pp. 1216–1243, 2025, doi: 10.1007/s12282-025-01779-3.

[45] G. Hasan, S. Singh, P. Gurav, S. M. Penumaka, S. Kumar, and S. Kumar, “Trastuzumab Resistance , a Potential Roadblock to the Most Successful Therapy for Breast Cancer – a Review of Underlying Mechanisms with Relevant Patents and Clinical Trials to Overcome the Resistance Trastuzumab Resistance , a Potential Roadblock to the Most Successful Therapy for Breast Cancer – A Review of Underlying Mechanisms with Relevant Patents,” pp. 0–36, 2025, doi: 10.20944/preprints202502.1188.v1.

[46] H. Maadi, M. H. Soheilifar, W.-S. Choi, A. Moshtaghian, and Z. Wang, “Trastuzumab Mechanism of Action; 20 Years of Research to Unravel a Dilemma.,” *Cancers (Basel).*, vol. 13, no. 14, Jul. 2021, doi: 10.3390/cancers13143540.

[47] O. Q. Bolaji, T. I. Adelusi, T. O. Ojo, and I. D. Boyenle, “Leveraging computational approaches in identifying novel HER - 2 + breast cancer potential therapeutics : integrating virtual screening and molecular dynamics simulation,” *Futur. J. Pharm. Sci.*, pp. 1–17, 2025, doi: 10.1186/s43094-024-00748-5.

[48] T. Tedavisi, A. Meme, K. Hastalarında, E. Patoloji, U. E. Kalınlık, and P. Örnekleme, “Endometrial Pathology in Tamoxifen-treated Breast Cancer Patients : Correlation of Endometrial Thickness on Ultrasound , Preoperative Sampling , and Final Pathology,” vol. 35, no. 2, pp. 178–184, 2025, doi: 10.4274/anatoljmed.2025.42385.

[49] E. Carvalho, S. Canberk, and F. Schmitt, “Molecular Subtypes and Mechanisms of Breast Cancer : Precision Medicine Approaches for Targeted Therapies,” 2025.

[50] C. Fébrissy *et al.*, “Theranostics Reprogramming of endothelial gene expression by tamoxifen inhibits angiogenesis and ER α -negative tumor growth,” vol. 14, no. 1, 2024, doi: 10.7150/thno.87306.

[51] N. Kim and K. E. Lukong, “Treating ER-positive breast cancer: a review of the current FDA-approved SERMs and SERDs and their mechanisms of action.,” *Oncol. Rev.*, vol. 19, p. 1564642, 2025, doi: 10.3389/or.2025.1564642.

[52] H. Lindman *et al.*, “Vaginal tamoxifen – A potential treatment option for vaginal atrophy symptoms in postmenopausal women who cannot use estrogen,” vol. 236, no. November 2025, 2026.

[53] C. Liu, F. Xu, and Q. Liu, “Tamoxifen-induced neutropenia and leukopenia in a breast cancer patient : a case report and literature review,” no. April, pp. 1–5, 2026, doi: 10.3389/fonc.2026.1691480.

[54] H. Puspaweni, Bambang Tri Purwanto, T. Widiandani, S. Siswodihardjo, and M. Artabah Muchlisin, “Thiourea Derivatives as Estrogen Receptor Alpha Inhibitors for Breast Cancer Therapy : An In Silico Evaluation with ADMET Prediction and Molecular Docking,” *Borneo J. Pharm.*, vol. 7, no. 3, pp. 278–289, 2024, doi: 10.33084/bjop.v7i3.7396.

[55] I. S. Pradipta *et al.*, “Traditional medicine users in a treated chronic disease population : a cross - sectional study in Indonesia,” *BMC Complement. Med. Ther.*, vol. 4, pp. 1–9, 2023, doi: 10.1186/s12906-023-03947-4.
[56] S. Choi *et al.*, “Traditional and Complementary Medicine Use among Cancer Patients in Asian Countries : A Systematic Review,” 2024.
[57] A. Afkar *et al.*, “Anticancer Therapeutic Potential Of Natural Products,” *J. desk Res. Rev. Anal.*, vol. 2, no. 1, pp. 67–91, 2024.
[58] A. Jenča *et al.*, “Herbal Therapies for Cancer Treatment : A Review of Phytotherapeutic Efficacy Herbal Therapies for Cancer Treatment : A Review of Phytotherapeutic Efficacy,” vol. 5475, 2024, doi: 10.2147/BTT.S484068.
[59] N. Putu, I. Widyantari, P. Made, and N. Armita, “Potensi Rimpang Temu Kunci (Boesenbergia pandurata Roxb .) sebagai Bahan Aktif Produk Kecantikan Alami yang Ramah Lingkungan,” vol. 1, pp. 82–100, 2022.
[60] F. I. Fahrudin, S. Phongthai, T. I. Wirjantoro, and P. Intipunya, “Synergistic Effects of Pressure , Temperature , CO 2 Flow Rate and Co-Solvent on Bioactive Contents of Thai Fingerroot (Boesenbergia rotunda (L .) Mansf .) Extracts,” no. 1, pp. 1–18, 2025.
[61] L. Khamsatul, M. Santoso, and S. Fatmawati, “Case Studies in Chemical and Environmental Engineering Chemical profiles , in silico pharmacokinetic and toxicity prediction of bioactive compounds from Boesenbergia rotunda,” *Case Stud. Chem. Environ. Eng.*, vol. 10, no. October, p. 100992, 2024, doi: 10.1016/j.cscee.2024.100992.
[62] A. Male, W. Rats, P. Ekstrak, E. Rimpang, T. Kunci, and L. Mansf, “The Potential of Ethanol Extract of Temu Kunci (Boesenbergia rotunda (L .) Mansf .),” vol. 9, pp. 24–30, 2024.
[63] W. Eiamart, S. Wittayalertpanya, S. Tadtong, and W. Samee, “Efficient Simultaneous Isolation of Pinostrobin and Panduratin A from Boesenbergia rotunda Using Centrifugal Partition Chromatography,” 2024.
[64] Y. Wang, J. Wen, F. Liu, X. Peng, and G. Xu, “Traditional usages , chemical metabolites , pharmacological activities , and pharmacokinetics of Boesenbergia rotunda (L .) Mansf .: a comprehensive review,” no. March, pp. 1–37, 2025, doi: 10.3389/fphar.2025.1527210.
[65] W. Eiamart, P. Wonganan, S. Tadtong, and W. Samee, “Panduratin A from Boesenbergia rotunda Effectively Inhibits EGFR / STAT3 / Akt Signaling Pathways , Inducing Apoptosis in NSCLC Cells with Wild-Type and T790M Mutations in EGFR,” 2025.
[66] N. Padauleng, M. Mustofa, T. D. Wahyuningsih, and D. Purnomosari, “Chalcone-3 Inhibits the Proliferation of Human Breast Cancer MDA-MB-231 Cell Line.,” *Asian Pac. J. Cancer Prev.*, vol. 24, no. 2, pp. 683–691, Feb. 2023, doi: 10.31557/APJCP.2023.24.2.683.
[67] M. H. Widyananda, L. Muflikhah, S. M. Ulfa, and N. Widodo, “Exploration of the bioactive compounds and potential mechanisms of fingerroot (Boesenbergia rotunda) as an anti-breast cancer by bioinformatics,” *Nat. Prod. Res.*, pp. 1–9, Oct. 2025, doi: 10.1080/14786419.2025.2559753.
[68] G. Rodrigues *et al.*, “European Journal of Medicinal Chemistry Reports

Design , synthesis and evaluation of quinazoline-chalcone hybrids as inducers of cell-cycle arrest and apoptosis in breast cancer via DNA damage and CDK2 / ATR inhibition," vol. 13, 2025, doi: 10.1016/j.ejmcr.2025.100250.

[69] N. S. Ibrahim, H. Ahmed, S. Marwa, S. Hadeer, and M. D. Ahmed, "Synthesis , cytotoxicity , anti - inflammatory , anti - metastatic and anti - oxidant activities of novel chalcones incorporating 2 - phenoxy - N - arylacetamide and thiophene moieties : induction of apoptosis in MCF7 and HEP2 cells," *Naunyn. Schmiedebergs. Arch. Pharmacol.*, vol. 397, no. 12, pp. 10091–10107, 2024, doi: 10.1007/s00210-024-03255-9.

[70] C. Gracesella, H. Patintingan, and M. Louisa, "Anticancer Potential of Chalcone and its Derivatives Against Triple Negative Breast Cancer Journal of Chemical Health Risks," vol. 14, pp. 309–316, 2024.

[71] C. Wai, J. Hunter, J. Ai, and J. E. Harnett, "Advances in Integrative Medicine Clinically beneficial interactions between biologically-based complementary medicines and cancer treatments – Protocol for a scoping review," *Adv. Integr. Med.*, vol. 12, no. 2, p. 100466, 2025, doi: 10.1016/j.aimed.2025.02.004.

[72] B. Pamungkas, A. D. Andriadi, and Z. Al-fajry, "Kajian Sistematis Potensi Interaksi Obat-Obat Herbal Terhadap Enzim Sitokrom P450 (CYP450) dan Implikasinya Pada Pasien Kanker Yang Menjalani Kemoterapi," vol. 10, pp. 640–645, 2026.

[73] Y. K. Putri, T. Rusdiana, F. Farmasi, and U. Padjadjaran, "PERBANDINGAN BERBAGAI INTERAKSI OBAT DENGAN HERBAL: ARTICLE REVIEW," *Farmaka*, vol. 14, no. 1, pp. 203–213, 2017.

[74] W. Jo, J. Chan, J. Adiwidjaja, A. J. Mclachlan, A. V Boddy, and J. E. Harnett, "Interactions between natural products and cancer treatments : underlying mechanisms and clinical importance," *Cancer Chemother. Pharmacol.*, pp. 103–119, 2023, doi: 10.1007/s00280-023-04504-z.

[75] X. Duan *et al.*, "Herb-drug interactions in oncology: pharmacodynamic/pharmacokinetic mechanisms and risk prediction.," *Chin. Med.*, vol. 20, no. 1, p. 107, Jul. 2025, doi: 10.1186/s13020-025-01156-4.

[76] S. Sabarathinam and N. Ganamurali, "Hyperforin as a non-steroidal modulator of the PXR–CYP3A4 regulatory axis: Mechanistic and computational insights into xenobiotic metabolism," *J. Steroid Biochem. Mol. Biol.*, vol. 256, p. 106886, 2026, doi: https://doi.org/10.1016/j.jsbmb.2025.106886.

[77] Y. Yuan *et al.*, "A new paradigm for drug discovery in the treatment of complex diseases : drug discovery and optimization," *Chin. Med.*, pp. 1–28, 2025, doi: 10.1186/s13020-025-01075-4.

[78] L. Zheng, J. Cao, L. Jing, D. Kang, Z. Wang, and X. Liu, "Convergence of computer-aided drug discovery and artificial intelligence: Towards next-generation therapeutics," *Pharm. Sci. Adv.*, vol. 4, p. 100100, 2026, doi: https://doi.org/10.1016/j.pscia.2025.100100.

[79] R. M. Ansari, R. N. Mundke, Y. O. Agrawal, S. N. Goyal, K. T. Nakhate, and S. S. Rathod, "Recent Advances in Molecular Docking Techniques: Transforming Perspectives in Distinct Drug Targeting and Drug Discovery Approaches.," *Med. Chem.*, Jul. 2025, doi: 10.2174/0115734064384472250716144736.

[80] M. Xue, B. Liu, S. Cao, and X. Huang, "FeatureDock for protein-ligand docking guided by physicochemical feature-based local environment learning using transformer," pp. 1–12, 2025.

[81] P. Chaturvedi and A. K. G. Chameli, "In Silico Molecular Docking of Bioactive Molecules : An Overview," *Int. J. Pharm. Life Sci.*, vol. 16, no. 10, pp. 21–26, 2025.

[82] H. K. Nivatya, A. Singh, N. Kumar, L. Sharma, V. Singh, and R. Mishra, "Assessing molecular docking tools : understanding drug discovery and design," 2025.

[83] B. Anusha and G. R. Kamala, "Principles and Applications of Molecular Docking in Drug Discovery and Development," no. 3048, 2025, doi: 10.69613/29zcv966.

[84] N. Mathur *et al.*, "In Silico Docking: Protocols for Computational Exploration of Molecular Interactions," Č. Podlipnik, Ed., London: IntechOpen, 2024. doi: 10.5772/intechopen.1005527.

[85] N. Çankaya and S. Yalçın, "ADMET , drug - likeness analyses of N - cyclohexylacrylamide : a first study on molecular docking and dynamic with DAPK1 and associated proteins," *Discov. Appl. Sci.*, 2025, doi: 10.1007/s42452-025-07143-6.

[86] R. V. Nugraha, "EVALUASI IN SILICO KAEMPFEROL SEBAGAI POTENSIAL INHIBITOR TIROSINASE : MOLECULAR DOCKING DAN PREDIKSI ADMET," vol. 6, pp. 14506–14514, 2025.

[87] Y. Wang, J. Xiao, T. O. Suzek, J. Zhang, J. Wang, and S. H. Bryant, "PubChem: a public information system for analyzing bioactivities of small molecules.," *Nucleic Acids Res.*, vol. 37, no. Web Server issue, pp. W623-33, Jul. 2019, doi: 10.1093/nar/gkp456.

[88] P. F. Ayodele and S. Farohunbi, "Illustrated Procedure to Perform Molecular Docking Using PyRx and Biovia Discovery Studio Visualizer : A Case Study of 10kt With Atropine," no. December, 2023, doi: 10.36877/pddbs.a0000424.

[89] Y. Chen, H. Zhang, and W. Wang, "Structural bioinformatics Rapid generation of high-quality structure figures for publication with PyMOL-PUB," vol. 40, no. March, pp. 0–2, 2024.

[90] N. F. Prasetio, J. Billy, and W. Bodhi, "Molecular Docking terhadap Senyawa Isoeleutherin dan Isoeleutherol sebagai Penghambat Pertumbuhan SARS-CoV-2," vol. 9, no. 1, pp. 101–106, 2021.

[91] S. K. Niazi, "Quantum Mechanics in Drug Discovery : A Comprehensive Review of Methods , Applications , and Future Directions," pp. 1–20, 2025.

[92] Siswandono, *Kimia Medisinal*, Edisi 1. surabaya: Airlangga University Press, 2016.

[93] M. A. Amelia, D. Kesuma, A. Kirtishanti, and M. Claudya, "Molecular

docking , synthesis , and in vitro activity testing of chalcone derivatives from Boesenbergia rotunda (L .) Mansf . against MCF-7 breast cancer cells," vol. 13, pp. 0–2, 2025.

[94] M. H. Widyananda *et al.*, "A Potential Anticancer Mechanism of Finger Root (Boesenbergia rotunda) Extracts against a Breast Cancer Cell Line," vol. 2022, 2022, doi: 10.1155/2022/9130252.

[95] M. Muchtaridi, H. N. Syahidah, A. Subarnas, and M. Yusuf, "Molecular Docking and 3D-Pharmacophore Modeling to Study the Interactions of Chalcone Derivatives with Estrogen Receptor Alpha," *pharmaceuticals*, vol. 10, no. 81, pp. 1–12, 2017, doi: 10.3390/ph10040081.

[96] C. Naruebodindra and S. Prakan, "Transcriptome analysis reveals a role of FOXO3 in antileukemia / lymphoma properties of panduratin," pp. 1–12, 2024.

[97] I. S. Edition, "Pinostrobin and its derivatives as novel anti-breast cancer agents against human oestrogen receptor alpha : In silico studies of ADMET , docking , and molecular dynamics," vol. 24, pp. 51–56, 2024.

[98] L. Clusan, F. Ferriere, G. Flouriot, and F. Pakdel, "A Basic Review on Estrogen Receptor Signaling Pathways in Breast Cancer," *Mol. Sci.*, vol. 24, no. 6834, 2023.

[99] C. Aguiar and I. Camps, "Molecular Docking in Drug Discovery: Techniques, Applications, and Advancements.," *Curr. Med. Chem.*, vol. 32, no. 28, pp. 5924–5938, 2025, doi: 10.2174/0109298673325827240926081845.

[100] A. Dashputra *et al.*, "Evaluation of tamoxifen analogues as potential estrogen receptor alpha inhibitors for breast cancer treatment: A computational approach," *J. Mol. Liq.*, vol. 414, p. 126209, 2024, doi: https://doi.org/10.1016/j.molliq.2024.126209.

[101] I. Bang *et al.*, "Selective targeting of oncogenic hotspot mutations of the HER2 extracellular domain," *Nat. Chem. Biol.*, vol. 21, no. 5, pp. 706–715, 2025, doi: 10.1038/s41589-024-01751-w.

[102] T. Pantsar and A. Poso, "Binding Affinity via Docking: Fact and Fiction," *Molecules*, vol. 23, no. 8. p. 1899, 2018. doi: 10.3390/molecules23081899.

[103] G. Simanullang, A. M. Rahayyu, N. A. Nabila, and A. Hammami, "Molecular docking and pharmacokinetic prediction of isoniazid and curcumin compounds against N-," vol. 2, no. 2, pp. 305–313, 2025.

[104] V. H. Masand *et al.*, "Estrogen Receptor Alpha Binders for Hormone-Dependent Forms of Breast Cancer: e-QSAR and Molecular Docking Supported by X-ray Resolved Structures.," *ACS omega*, vol. 9, no. 14, pp. 16759–16774, Apr. 2024, doi: 10.1021/acsomega.4c00906.

[105] S. H. Giordano *et al.*, "Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Guideline Update," *J. Clin. Oncol.*, vol. 40, no. 23, pp. 2612–2635, May 2022, doi: 10.1200/JCO.22.00519.

[106] A. Marra, S. Chandarlapaty, and S. Modi, "Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives," *Nat. Rev. Clin. Oncol.*, vol. 21, no. 3, pp. 185–202, 2024, doi:

10.1038/s41571-023-00849-9.
[107] S. Mangmool, B. Nutho, and D. Pinthong, “Anticancer Effect of Pinostrobin on Human Breast Cancer Cells Through Regulation of Epithelial Mesenchymal Transition,” 2025, doi: 10.1177/15347354251341438.
[108] J. M. Paggi, A. Pandit, and R. O. Dror, “The Art and Science of Molecular Docking,” *Annu. Rev.*, no. 93, pp. 389–410, 2024.
[109] Z. Ma, A. Ajibade, and X. Zou, “Docking strategies for predicting protein-ligand interactions and their application to structure-based drug design.,” *Commun. Inf. Syst.*, vol. 24, no. 3, pp. 199–230, 2024, doi: 10.4310/cis.241021221101.
[110] S. Ilango, B. Yadurappa, S. Kumar, and K. Girija, “Molecular docking analysis of pyrrole derivatives with the human epidermal growth factor receptor 2 : Combating breast cancer,” vol. 21, no. 5, pp. 1075–1081, 2025, doi: 10.6026/973206300211075.
[111] A. Ranaudo, U. Cosentino, C. Greco, G. Moro, A. Maiocchi, and E. Moroni, “Guiding Competitive Binding Assays Using Protein-Protein Interaction Prediction: The HER2-Affitin Use Case.,” *ACS omega*, vol. 9, no. 50, pp. 49522–49529, Dec. 2024, doi: 10.1021/acsomega.4c07317.
[112] L. Wang *et al.*, “Resistance mechanisms and prospects of trastuzumab,” no. November, pp. 1–12, 2024, doi: 10.3389/fonc.2024.1389390.
[113] D. Ramdhani, S. A. F. Kusuma, and M. Kusmiati, “In-Silico Studies of Musa balbisiana Colla with Proteins Promoting Antibiotic Resistance in Bacterial and Fungal Pathogens Studi In-Silico Musa balbisiana Colla dengan Protein yang Meningkatkan Resistensi Antibiotik pada Patogen Bakteri dan Jamur,” vol. 11, no. 2, 2024.
[114] F. M. G. Cornelissen *et al.*, “Explaining Blood–Brain Barrier Permeability of Small Molecules by Integrated Analysis of Different Transport Mechanisms,” *J. Med. Chem.*, vol. 66, no. 11, pp. 7253–7267, Jun. 2023, doi: 10.1021/acs.jmedchem.2c01824.
[115] S. A. R. Sancha, N. Szemerédi, G. Spengler, and M.-J. U. Ferreira, “Lycorine Carbamate Derivatives for Reversing P-glycoprotein-Mediated Multidrug Resistance in Human Colon Adenocarcinoma Cells.,” *Int. J. Mol. Sci.*, vol. 24, no. 3, Jan. 2023, doi: 10.3390/ijms24032061.
[116] E. Elamin *et al.*, “Updates on the Interactions of Herbs Constituents with Cytochrome P450 Drug Metabolizing Enzymes,” pp. 167–178, 2023, doi: 10.2174/1573408019666230601121657.
[117] W. Cheng, K. Xia, S. Wu, and Y. Li, “Herb-Drug Interactions and Their Impact on Pharmacokinetics: An Update,” *Current Drug Metabolism*, vol. 24, no. 1. pp. 28–69, 2023. doi: http://dx.doi.org/10.2174/1389200224666230116113240.
[118] M. Li *et al.*, “A comprehensive review on pharmacokinetic mechanism of herb-herb/drug interactions in Chinese herbal formula,” *Pharmacol. Ther.*, vol. 264, p. 108728, 2024, doi: https://doi.org/10.1016/j.pharmthera.2024.108728.
[119] E. E. H. Zaroug, T. O. A. Albashir, A. H. Arbab, and M. M. E. Mudawi, “Updates on the Interactions of Herbs Constituents with Cytochrome P450

Drug Metabolizing Enzymes," *Current Enzyme Inhibition*, vol. 19, no. 3. pp. 167–178, 2023. doi: http://dx.doi.org/10.2174/1573408019666230601121657.

[120] Y. Li *et al.*, "Effects of schisandra lignans on the absorption of protopanaxadiol-type ginsenosides mediated by P-glycoprotein and protopanaxatriol-type ginsenosides mediated by CYP3A4," *J. Ethnopharmacol.*, vol. 318, p. 117057, 2024, doi: https://doi.org/10.1016/j.jep.2023.117057.

[121] Y. L. Zhang, S. J. Sun, and L. Zeng, "Biological effects and mechanisms of dietary chalcones: latest research progress, future research strategies, and challenges," *Food Funct.*, vol. 15, no. 21, pp. 10582–10599, Nov. 2024, doi: 10.1039/d4fo03618b.

[122] A. Verma, S. Wu, and D. K. Shah, "Oral Bioavailability of Monoclonal Antibody.," *Pharmaceutics*, vol. 18, no. 1, Dec. 2025, doi: 10.3390/pharmaceutics18010022.

[123] A. S. Pirzada *et al.*, "Physicochemical properties, pharmacokinetic studies, DFT approach, and antioxidant activity of nitro and chloro indolinone derivatives," *Front. Chem.*, vol. Volume 12-2024, 2024, [Online]. Available: https://www.frontiersin.org/journals/chemistry/articles/10.3389/fchem.2024.1360719

[124] J. Moreira *et al.*, "Structure-Activity Relationship Studies of Chalcones and Diarylpentanoids with Antitumor Activity: Potency and Selectivity Optimization.," *Pharmaceuticals (Basel).*, vol. 16, no. 10, Sep. 2023, doi: 10.3390/ph16101354.

[125] D. Patel, N. Sethi, P. Patel, S. Shah, and K. Patel, "Exploring the potential of P-glycoprotein inhibitors in the targeted delivery of anti-cancer drugs: A comprehensive review.," *Eur. J. Pharm. Biopharm. Off. J. Arbeitsgemeinschaft fur Pharm. Verfahrenstechnik e.V*, vol. 198, p. 114267, May 2024, doi: 10.1016/j.ejpb.2024.114267.

[126] A. Daina, O. Michielin, and V. Zoete, "SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules.," *Sci. Rep.*, vol. 7, p. 42717, Mar. 2017, doi: 10.1038/srep42717.